Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Xiaoying Zhao(Handan College), Zhiyu Chen(Chongqing University), Wen Zhang(Fudan University Shanghai Cancer Center), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Weijian Guo, Chen Chen Wang(Fudan University Shanghai Cancer Center)

Journal of Clinical Oncology

February 1, 2017

10.1200/jco.2017.35.4_suppl.469

Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

|JAMA|2018|410

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

|JAMA|2023|384

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247